Anti-IL11 Antibody (X203) (20 mg/kg, intraperitoneal injection, twice a week starting from 6 weeks of age, lasting for 2.5 weeks) can improve renal function and prolong the lifespan of Alport syndrome (AS) mouse models.
| Animal Model: |
Wild-type mice injected with BLM |
| Dosage: |
20 mg/kg |
| Administration: |
i.p., alternate days from day 7 to 21 after BLM |
| Result: |
Showed no effect on overall survival.
Greatly reduced lung hydroxyproline content.
Reduced the expression of ECM-related genes.
Increased Mmp2/Timp1 ratio (a signature of preferential ECM remodeling) compared to control.
Markedly reduced ERK and SMAD activation whereas STAT3 phosphorylation remained elevated. |